David B Rozema

Summary

Affiliation: Mirus Bio Corporation
Country: USA

Publications

  1. ncbi Hepatocyte targeting of nucleic acid complexes and liposomes by a T7 phage p17 peptide
    So C Wong
    Mirus Bio Corporation, 505 South Rosa Road, Madison, Wisconsin 53719, USA
    Mol Pharm 3:386-97. 2006
  2. ncbi Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes
    David B Rozema
    Mirus Bio Corporation, 505 South Rosa Road, Madison, WI 53719, USA
    Proc Natl Acad Sci U S A 104:12982-7. 2007
  3. ncbi Breaking the bonds: non-viral vectors become chemically dynamic
    Jon A Wolff
    Waisman Center, Department of Pediatrics and Medical Genetics, University of Wisconsin Madison, Madison, Wisconsin, USA
    Mol Ther 16:8-15. 2008
  4. ncbi Membrane activity and transfection ability of amphipathic polycations as a function of alkyl group size
    Darren H Wakefield
    Mirus Bio Corporation, 505 S. Rosa Road, Madison, Wisconsin 53711, USA
    Bioconjug Chem 16:1204-8. 2005
  5. ncbi Endosomolysis by masking of a membrane-active agent (EMMA) for cytoplasmic release of macromolecules
    David B Rozema
    Mirus Corporation, 505 S Rosa Road, Madison, Wisconsin 53711, USA
    Bioconjug Chem 14:51-7. 2003

Research Grants

  1. Delivery of Oligonucleotides to Hepatocytes In Vivo
    David Rozema; Fiscal Year: 2005
  2. Amphiphilic Polycations for Nucleic Acid Delivery
    David Rozema; Fiscal Year: 2007

Collaborators

Detail Information

Publications5

  1. ncbi Hepatocyte targeting of nucleic acid complexes and liposomes by a T7 phage p17 peptide
    So C Wong
    Mirus Bio Corporation, 505 South Rosa Road, Madison, Wisconsin 53719, USA
    Mol Pharm 3:386-97. 2006
    ..This was primarily due to failure of delivered cargo to escape the endosomes. Further studies are in progress to provide functional activity of delivered nucleic acids by enabling their endosomal escape...
  2. ncbi Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes
    David B Rozema
    Mirus Bio Corporation, 505 South Rosa Road, Madison, WI 53719, USA
    Proc Natl Acad Sci U S A 104:12982-7. 2007
    ..Analyses of serum liver enzyme and cytokine levels in treated mice indicated that the siRNA Dynamic PolyConjugate was nontoxic and well tolerated...
  3. ncbi Breaking the bonds: non-viral vectors become chemically dynamic
    Jon A Wolff
    Waisman Center, Department of Pediatrics and Medical Genetics, University of Wisconsin Madison, Madison, Wisconsin, USA
    Mol Ther 16:8-15. 2008
    ..The use of labile bonds to mask endosomolytic agents, provides a critical design feature, because it enables efficient in vivo delivery without sacrificing endosomolytic function for release into the cytoplasm...
  4. ncbi Membrane activity and transfection ability of amphipathic polycations as a function of alkyl group size
    Darren H Wakefield
    Mirus Bio Corporation, 505 S. Rosa Road, Madison, Wisconsin 53711, USA
    Bioconjug Chem 16:1204-8. 2005
    ....
  5. ncbi Endosomolysis by masking of a membrane-active agent (EMMA) for cytoplasmic release of macromolecules
    David B Rozema
    Mirus Corporation, 505 S Rosa Road, Madison, Wisconsin 53711, USA
    Bioconjug Chem 14:51-7. 2003
    ..This approach avoids cellular toxicity by restricting melittin's activity until it reaches the endosomal compartment. The utility of this approach was demonstrated by delivery phosphorodiamidate morpholino oligonucleotides (PMOs)...

Research Grants3

  1. Delivery of Oligonucleotides to Hepatocytes In Vivo
    David Rozema; Fiscal Year: 2005
    ....
  2. Amphiphilic Polycations for Nucleic Acid Delivery
    David Rozema; Fiscal Year: 2007
    ....